About Glaukos (NYSE:GKOS)
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. Glaukos Corporation markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. The company was founded in 1998 and is headquartered in San Clemente, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GKOS
CUSIPN/A
Phone949-367-9600
Debt
Debt-to-Equity RatioN/A
Current Ratio5.58%
Quick Ratio5.16%
Price-To-Earnings
Trailing P/E Ratio198.33
Forward P/E Ratio-79.82
P/E GrowthN/A
Sales & Book Value
Annual Sales$159.25 million
Price / Sales6.63
Cash Flow$0.1595 per share
Price / Cash190.15
Book Value$4.00 per share
Price / Book7.58
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-90,000.00
Net Margins-0.06%
Return on Equity4.03%
Return on Assets3.47%
Miscellaneous
Employees387
Outstanding Shares34,830,000
Glaukos (NYSE:GKOS) Frequently Asked Questions
What is Glaukos' stock symbol?
Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."
How were Glaukos' earnings last quarter?
Glaukos Corp (NYSE:GKOS) posted its quarterly earnings results on Wednesday, February, 28th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.02. The medical instruments supplier earned $41.65 million during the quarter, compared to the consensus estimate of $40.83 million. Glaukos had a negative net margin of 0.06% and a positive return on equity of 4.03%. The business's revenue was up 25.6% on a year-over-year basis. View Glaukos' Earnings History.
When is Glaukos' next earnings date?
What price target have analysts set for GKOS?
8 equities research analysts have issued 12 month price objectives for Glaukos' shares. Their forecasts range from $32.00 to $54.00. On average, they anticipate Glaukos' share price to reach $40.2857 in the next year. View Analyst Ratings for Glaukos.
What are Wall Street analysts saying about Glaukos stock?
Here are some recent quotes from research analysts about Glaukos stock:
- 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (2/13/2018)
- 2. Cantor Fitzgerald analysts commented, "Executing Well in a Slightly Adverse Environment. Glaukos reported 37% YoY revenue growth, falling a little short of the 40%+ growth since the launch of iStent slightly more than four years ago (88% of the sales were recorded in the U.S.). The company reported to be on track to have trained >3,000 surgeons by YE17. Glaukos operated in an environment, which was affected by a number of factors: 1: the slow institution of higher reimbursement (challenging during implementation, but favorable afterwards) by commercial payors (20% of total); 2: hurricane-caused delays in surgery ($1 million impact in 3Q17); 3: a negative impact by a single Medicare operator (lowering surgeon’s fees) and by continued sampling and perhaps early sales by competitor Alcon (wholly owned by NVS [Not Covered]). Long term, we believe Glaukos’ iStent has demonstrated significant long-term benefit and cost efficiency to maintain a commercial and competitive advantage. The company remained cautious about 2018, due to the expanded launch by Alcon, a second competitor potentially arriving to the market by 2H18 (Hydrus by Ivantis [private]) and the relatively modest contribution by iStent Inject (PMA to be submitted by YE17). 2018 guidance will be introduced in January at the 4Q17 earnings call." (11/7/2017)
Who are some of Glaukos' key competitors?
Some companies that are related to Glaukos include Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), CryoLife (CRY), Cardiovascular Systems (CSII), AtriCure (ATRC), AngioDynamics (ANGO), Cerus (CERS), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD) and SurModics (SRDX).
Who are Glaukos' key executives?
Glaukos' management team includes the folowing people:
- Mr. Thomas William Burns, CEO, Pres & Director (Age 57)
- Mr. Chris M. Calcaterra, Chief Operating Officer (Age 58)
- Mr. Richard L. Harrison, Advisor (Age 61)
- Dr. Mory Gharib Ph.D., Co-Founder
- Mr. Joseph E. Gilliam, CFO & Sr. VP - Corp. Devel.
When did Glaukos IPO?
(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.
Has Glaukos been receiving favorable news coverage?
Press coverage about GKOS stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Glaukos earned a daily sentiment score of 0.00 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 45.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Glaukos?
Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Glaukos' stock price today?
One share of GKOS stock can currently be purchased for approximately $30.33.
How big of a company is Glaukos?
Glaukos has a market capitalization of $1.04 billion and generates $159.25 million in revenue each year. Glaukos employs 387 workers across the globe.
How can I contact Glaukos?
Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]
MarketBeat Community Rating for Glaukos (GKOS)
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Glaukos (NYSE:GKOS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Glaukos in the last 12 months. Their average twelve-month price target is $40.2857, suggesting that the stock has a possible upside of 32.82%. The high price target for GKOS is $54.00 and the low price target for GKOS is $32.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.88 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $40.2857 | $41.2857 | $45.50 | $49.8333 |
| Price Target Upside: | 32.82% upside | 38.40% upside | 61.35% upside | 52.86% upside |
Glaukos (NYSE:GKOS) Consensus Price Target History
Glaukos (NYSE:GKOS) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Glaukos (NYSE:GKOS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Glaukos (NYSE GKOS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.40%
Glaukos (NYSE GKOS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/6/2018 | Orbimed Advisors Llc | Director | Sell | 836,500 | $32.02 | $26,784,730.00 | |  |
| 3/2/2018 | Jonathan Silverstein | Director | Sell | 464,583 | $32.29 | $15,001,385.07 | | |
| 11/22/2017 | Joseph E Gilliam | CFO | Buy | 2,100 | $23.84 | $50,064.00 | 102,100 | |
| 9/7/2017 | Thomas William Burns | CEO | Sell | 73,788 | $41.36 | $3,051,871.68 | | |
| 9/5/2017 | Orbimed Advisors Llc | Director | Sell | 580,200 | $38.73 | $22,471,146.00 | | |
| 9/5/2017 | Thomas William Burns | CEO | Sell | 1,212 | $41.25 | $49,995.00 | | |
| 8/17/2017 | Orbimed Advisors Llc | Director | Sell | 325,000 | $37.93 | $12,327,250.00 | | |
| 3/14/2017 | Orbimed Advisors Llc | Director | Sell | 382,538 | $45.33 | $17,340,447.54 | | |
| 2/2/2017 | Thomas William Burns | CEO | Sell | 50,000 | $42.58 | $2,129,000.00 | | |
| 1/13/2017 | Chris M Calcaterra | Insider | Sell | 18,136 | $40.01 | $725,621.36 | 254,413 | |
| 1/13/2017 | Richard L Harrison | CFO | Sell | 20,634 | $40.00 | $825,360.00 | 15,709 | |
| 1/9/2017 | Chris M Calcaterra | Insider | Sell | 20,000 | $38.02 | $760,400.00 | 260,000 | |
| 1/9/2017 | Thomas William Burns | CEO | Sell | 40,000 | $37.60 | $1,504,000.00 | | |
| 1/6/2017 | Richard L Harrison | CFO | Sell | 20,634 | $35.58 | $734,157.72 | 2,656 | |
| 11/17/2016 | William J Phd Link | Director | Sell | 30,000 | $33.78 | $1,013,400.00 | | |
| 11/15/2016 | Thomas William Burns | CEO | Sell | 200,120 | $33.68 | $6,740,041.60 | 1,388 | |
| 10/24/2016 | Chris M Calcaterra | Insider | Sell | 20,000 | $36.01 | $720,200.00 | 260,000 | |
| 10/20/2016 | Chris M Calcaterra | Insider | Sell | 40,000 | $34.76 | $1,390,400.00 | 280,000 | |
| 8/12/2016 | Jonathan Silverstein | Director | Sell | 292,938 | $33.69 | $9,869,081.22 | | |
| 8/3/2016 | Orbimed Advisors Llc | Director | Sell | 425,000 | $30.59 | $13,000,750.00 | | |
| 7/27/2016 | Richard L Harrison | CFO | Sell | 10,000 | $35.01 | $350,100.00 | 11,388 | |
| 7/13/2016 | Thomas William Burns | CEO | Sell | 162,254 | $30.07 | $4,878,977.78 | 1,388 | |
| 7/12/2016 | Richard L Harrison | CFO | Sell | 5,700 | $30.00 | $171,000.00 | 7,088 | |
| 6/20/2016 | Richard L Harrison | CFO | Sell | 4,300 | $30.00 | $129,000.00 | 5,688 | |
| 6/20/2016 | Thomas William Burns | CEO | Sell | 7,997 | $30.00 | $239,910.00 | 1,388 | |
| 6/15/2016 | Chris M Calcaterra | Insider | Sell | 45,464 | $28.46 | $1,293,905.44 | 273,600 | |
| 6/6/2016 | Thomas William Burns | CEO | Sell | 24,578 | $25.16 | $618,382.48 | 1,388 | |
| 6/3/2016 | Thomas William Burns | CEO | Sell | 422 | $25.00 | $10,550.00 | 1,388 | |
| 6/1/2016 | Thomas William Burns | CEO | Sell | 25,000 | $23.90 | $597,500.00 | 1,388 | |
| 5/25/2016 | Thomas William Burns | CEO | Sell | 300 | $25.00 | $7,500.00 | 1,388 | |
| 5/4/2016 | Chris M Calcaterra | Insider | Sell | 74,536 | $24.40 | $1,818,678.40 | 245,836 | |
| 5/4/2016 | Richard L Harrison | CFO | Sell | 30,000 | $24.59 | $737,700.00 | 3,556 | |
| 5/4/2016 | Thomas William Burns | CEO | Sell | 36,700 | $24.67 | $905,389.00 | 1,388 | |
| 3/4/2016 | Aimee S Weisner | Director | Buy | 2,500 | $16.03 | $40,075.00 | | |
| 2/25/2016 | Montreux Equity Partners Iv Lp | Major Shareholder | Sell | 70,000 | $16.16 | $1,131,200.00 | | |
| 12/31/2015 | Richard L Harrison | CFO | Buy | 1,388 | $15.30 | $21,236.40 | 4,656 | |
| 11/12/2015 | Aimee S Weisner | Director | Buy | 2,500 | $21.83 | $54,575.00 | 2,500 | |
(Data available from 1/1/2013 forward)
Glaukos (NYSE GKOS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Glaukos (GKOS) Raised to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 10:12 PM |
 | Glaukos Corporation to Release First Quarter 2018 Financial Results after Market Close on May 9
finance.yahoo.com - April 19 at 5:14 PM |
| Glaukos (GKOS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:28 AM |
| Glaukos (GKOS) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 18 at 6:22 PM |
| Piper Jaffray Comments on Glaukos Corp's Q1 2019 Earnings (GKOS)
www.americanbankingnews.com - April 18 at 8:42 AM |
| FY2020 EPS Estimates for Glaukos Corp Cut by Analyst (GKOS)
www.americanbankingnews.com - April 17 at 7:05 AM |
 | ALNY On Watch, NLNK Exhibits Caution, Keep An Eye On GKOS
www.nasdaq.com - April 16 at 8:43 AM |
 | Glaukos Corporation (GKOS) Reports 2-Yr US IDE Pivotal Trial Results for iStent Inject Show Significant Reductions in ...
www.streetinsider.com - April 16 at 8:43 AM |
| Glaukos Corporation (GKOS) Reports Filing of Patent Infringement Lawsuit Against Ivantis Inc.
www.streetinsider.com - April 16 at 8:43 AM |
| Financial Review: Glaukos (GKOS) versus STRATA Skin Sciences (SSKN)
www.americanbankingnews.com - April 15 at 9:24 PM |
| IDE Pivotal Trial Results for Glaukos’ iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery
finance.yahoo.com - April 14 at 4:49 PM |
| Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.
finance.yahoo.com - April 14 at 8:52 AM |
| Glaukos (GKOS) Cut to Sell at ValuEngine
www.americanbankingnews.com - April 13 at 11:10 PM |
| Roth Capital Cuts Glaukos (GKOS) Price Target to $54.00
www.americanbankingnews.com - April 13 at 5:29 PM |
 | 5 Biggest Price Target Changes For Friday
www.benzinga.com - April 13 at 5:08 PM |
| Stifel's Doctor Survey Triggers Glaukos Downgrade
finance.yahoo.com - April 13 at 5:08 PM |
| Why Glaukos Corp. Is Sinking Today
finance.yahoo.com - April 13 at 5:08 PM |
| Glaukos (GKOS) Rating Lowered to Hold at Stifel Nicolaus
www.americanbankingnews.com - April 13 at 10:37 AM |
| Stifel Downgrades Glaukos Corporation (GKOS) to Hold
www.streetinsider.com - April 13 at 8:58 AM |
| Zacks: Analysts Anticipate Glaukos Corp (GKOS) Will Announce Quarterly Sales of $38.72 Million
www.americanbankingnews.com - April 12 at 5:55 AM |
| Glaukos Corp (GKOS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 1:14 PM |
 | Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive ...
www.businesswire.com - April 11 at 9:10 AM |
| Analysts Anticipate Glaukos Corp (GKOS) to Post -$0.12 EPS
www.americanbankingnews.com - April 10 at 1:24 AM |
 | Pre-Market Technical Scan on Medical Supplies Equities -- Daxor, Endologix, Glaukos, and Halyard Health
www.prnewswire.com - April 9 at 8:58 AM |
| Glaukos (GKOS) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - April 9 at 1:01 AM |
| Glaukos (GKOS) Earns Buy Rating from BMO Capital Markets
www.americanbankingnews.com - April 6 at 5:52 PM |
| Glaukos (GKOS) Upgraded at ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM |
| Glaukos (GKOS) Price Target Cut to $40.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - April 1 at 9:47 AM |
| Cantor Fitzgerald Analysts Give Glaukos (GKOS) a $48.00 Price Target
www.americanbankingnews.com - March 28 at 8:42 PM |
| Edited Transcript of GKOS earnings conference call or presentation 28-Feb-18 9:30pm GMT
finance.yahoo.com - March 26 at 4:53 PM |
| Glaukos Corp (GKOS) Expected to Post Quarterly Sales of $38.72 Million
www.americanbankingnews.com - March 26 at 8:23 AM |
| Glaukos (GKOS) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 3:47 PM |
| Brokerages Expect Glaukos Corp (GKOS) to Post -$0.11 EPS
www.americanbankingnews.com - March 24 at 1:16 AM |
| William Blair Reiterates Outperform Rating for Glaukos (GKOS)
www.americanbankingnews.com - March 23 at 3:28 PM |
| Glaukos (GKOS) PT Set at $43.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 23 at 1:30 PM |
| Glaukos Corp (GKOS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 1:43 PM |
| Glaukos Corp (GKOS) to Post FY2018 Earnings of ($0.70) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - March 7 at 11:53 AM |
| Orbimed Advisors Llc Sells 836,500 Shares of Glaukos Corp (GKOS) Stock
www.americanbankingnews.com - March 6 at 9:28 PM |
| Glaukos Corp (GKOS) Director Jonathan Silverstein Sells 464,583 Shares
www.americanbankingnews.com - March 6 at 9:27 PM |
| -$0.08 Earnings Per Share Expected for Glaukos Corp (GKOS) This Quarter
www.americanbankingnews.com - March 6 at 7:17 PM |
| Glaukos Corp to Post FY2018 Earnings of ($0.69) Per Share, William Blair Forecasts (GKOS)
www.americanbankingnews.com - March 5 at 5:38 AM |
| Glaukos Announces Participation in 30th Annual ROTH Conference
finance.yahoo.com - March 2 at 8:44 AM |
| Stephens Reaffirms Buy Rating for Glaukos (GKOS)
www.americanbankingnews.com - March 1 at 6:44 PM |
| Glaukos (GKOS) Stock Rating Reaffirmed by William Blair
www.americanbankingnews.com - March 1 at 5:46 PM |
| Glaukos (GKOS) PT Lowered to $43.00 at Canaccord Genuity
www.americanbankingnews.com - March 1 at 5:46 PM |
| BMO Capital Markets Trims Glaukos (GKOS) Target Price to $36.00
www.americanbankingnews.com - March 1 at 2:02 PM |
| Glaukos (GKOS) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 28 at 7:04 PM |
| Glaukos Q4 Earnings Outlook
finance.yahoo.com - February 28 at 5:37 PM |
| Glaukos Corporation Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 28 at 5:37 PM |
| Glaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society Meeting
finance.yahoo.com - February 27 at 5:32 PM |
Glaukos (NYSE:GKOS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Glaukos (NYSE:GKOS) Income Statement, Balance Sheet and Cash Flow Statement
Glaukos (NYSE GKOS) Stock Chart for Monday, April, 23, 2018
Loading chart…
